Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate
eLife · 2025
DOI: 10.7554/elife.101128 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Hang Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Research Center for Protozoan Diseases, Obihiro University of Agriculture Veterinary Medicine, Obihiro, Japan. Hauptthemen laut MEDLINE: Babesia, Antiprotozoal Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Ministry of Agriculture, Forestry and Fisheries.
Abstract (Originalsprache)
Babesiosis is a disease brought on by intraerythrocytic parasites of the genus Babesia . Current chemotherapies are accompanied by side effects and parasite relapse. Therefore, it is crucial to develop highly effective drugs against Babesia . Cipargamin (CIP) has shown inhibition against apicomplexan parasites, mainly Plasmodium and Toxoplasma . This study evaluated the growth-inhibiting properties of CIP against Babesia spp. and investigated the mechanism of CIP on B. gibsoni . The half inhibitory concentration (IC 50 ) values of CIP against the in vitro growth of B. bovis and B. gibsoni were 20.2 ± 1.4 and 69.4 ± 2.2 nM, respectively. CIP significantly inhibited the growth of B. microti and B. rodhaini in vivo. Resistance was conferred by L921V and L921I mutations in BgATP4, which reduced the sensitivity to CIP by 6.1- and 12.8-fold. The inhibitory potency of CIP against BgATP4-associated ATPase activity was moderately reduced in mutant strains, with a 1.3- and 2.4-fold decrease in BgATP4 L921V and BgATP4 L921I , respectively, compared to that of BgATP4 WT . An in silico investigation revealed reductions in affinity for CIP binding to BgATP4 L921V and BgATP4 L921I compared to BgATP4 WT . Resistant strains showed no significant cross-resistance to atovaquone or tafenoquine succinate (TQ), with less than a onefold change in IC 50 values. Combining CIP with TQ effectively eliminated B. microti infection in SCID mice with no relapse, and parasite DNA was not detected by qPCR within 90 days post-infection. Our findings reveal the efficacy of CIP as an antibabesial agent, its limitations as a monotherapy due to resistance development, and the potential of combination therapy with TQ to overcome said resistance and achieve complete parasite clearance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Research Center for Protozoan Diseases, Obihiro University of Agriculture Veterinary Medicine, Obihiro, Japan.
- Department of Veterinary Medicine, Agriculture College of Yanbian University, Yanji, China.
- College of Veterinary Medicine and Biomedical Sciences, Cavite State University, Indang, Philippines.
- Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt.
- Central Laboratory, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan.
- School of Basic Medicine, Hubei University of Arts and Science, Xiangyang, China.
ORCID-Profile: Hang Li, Shengwei Ji, Nanang R Ariefta, Eloiza May S Galon, Masahito Asada, Yoshifumi Nishikawa, Xin Qin, Mingming Liu, Xuenan Xuan
Förderung
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Agriculture, Forestry and Fisheries
Zitieren
APA
Li, H., Ji, S., Ariefta, N. R., Galon, E. M. S., El-Sayed, S. A. E. S., Do, T., Jia, L., Sakaguchi, M., Asada, M., Nishikawa, Y., Qin, X., Liu, M., & Xuan, X. (2025). Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate. eLife. https://doi.org/10.7554/elife.101128
Vancouver
Li H, Ji S, Ariefta NR, Galon EMS, El-Sayed SAES, Do T, et al. Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate. eLife. 2025. doi:10.7554/elife.101128
BibTeX
@article{Li2025,
author = {Li, Hang and Ji, Shengwei and Ariefta, Nanang R and Galon, Eloiza May S and El-Sayed, Shimaa A E S and Do, Thom and Jia, Lijun and Sakaguchi, Miako and Asada, Masahito and Nishikawa, Yoshifumi and Qin, Xin and Liu, Mingming and Xuan, Xuenan},
title = {Efficacy and mechanism of action of cipargamin as an antibabesial drug candidate},
journal = {eLife},
year = {2025},
doi = {10.7554/elife.101128}
}
EUVIMED